ArticleHereditas2025
miR-423-5p mediates LINC00886 regulation of ovarian cancer aggressiveness and immune evasion via the TLR4/Myd88/NF-κB/PD-L1 pathway.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- p62/SQSTM1-TRAF6/RIP1 complexes activate NF-κB-mediated PD-L1 expression and promote T-cell apoptosis in MKN45 gastric cancer cells.Journal of gastrointestinal oncology · 2026Article
- LINC00886 inhibits the proliferation, migration, and invasion of NSCLC cells by sponging miR-141-5p.Discover oncology · 2026Article
- Recent advances in the role of long non-coding RNAs in ovarian cancer chemoresistance.Journal of ovarian research · 2026Review
- Glycolytic reprogramming in ovarian cancer: mechanisms, immune crosstalk, and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer has poor treatment outcomes. This study aims to explore the clinical importance of LINC00886 and its effects on cancer cell behavior in ovarian cancer, potentially offering a new therapeutic target. MATERIALS AND
methodsRT-qPCR was used to detect LINC00886 expression in ovarian cancer tissue, with analysis of clinicopathological data and prognosis based on LINC00886 expression levels. CCK-8, Traswell, and Annexin V-FITC/PI flow cytometry assays were used to evaluate the impact of molecular expression on cell viability, invasiveness, and apoptosis. RIP and dual luciferase reporter gene assays were used to validate interactions among miR-423-5p, LINC00886, and TLR4. Western blot analysis was conducted to investigate downstream signaling proteins, and ELISA was used to measure TNF-α and IFN-γ levels in cell co-culture.
resultsLINC00886 is upregulated in ovarian cancer tissues and cell lines, and its high expression is associated with poor prognosis; downregulating LINC00886 inhibits cell viability and invasiveness while inducing apoptosis. miR-423-5p is downstream of LINC00886 and upstream of TLR4. Inhibiting miR-423-5p reverses the suppressive effects of LINC00886 downregulation on cancer cell behavior. Overexpressing TLR4 enhances cellular processes. Furthermore, downregulating LINC00886 reduces the expression of TLR4, Myd88, phosphorylated NF-κB p65, and PD-L1, while increasing TNF-α and IFN-γ levels and enhancing CD8 + T cell antitumor activity, thereby reducing tumor cell immune escape.
conclusionsLINC00886 drives ovarian cancer progression and immune escape through themiR-423-5p/TLR4/Myd88/NF-κB/PD-L1 axis, establishing its potential as both a prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.